Advanced Search

 

Study ID Status Title Patient Level Data
S3AT20 Completed Comparison of Ondansetron vs Ondansetron + Dexamethasone in the control of delayed emesis and nausea induced by Cisplatin.
S3AV01 Completed A randomised, double-blind, placebo controlled, multicentre, parallel group study to evaluate the efficacy and safety of a single intravenous bolus dose of ondansetron in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing elective abdominal su ...
S3AV02 Completed A randomised, double-blind, placebo controlled, multicentre, parallel group study to evaluate the efficacy and safety of a single intravenous bolus dose of ondansetron in the prevention of postoperative nausea and emesis in patients having general anaesthesia and undergoing major gynaecological ...
S3B10903 Completed An Open-Label, Non-Randomized, Single-Dose Study of the Pharmacokinetics of Alosetron 1mg in Children 6-11 Years of Age With Non-Constipated Irritable Bowel Syndrome
S3B10909 Completed Alosetron (GR68755): Phase I study (evaluation of the effect of food in healthy volunteer).
S3B10910 Completed To assess the effects of GR68755C on psychological and psychomotor responses to amphetamine in healthy volunteers.
S3B10916 Completed A study to evaluate the effects of GR68755 on memory and information processing when co-administered with scopolamine in young healthy volunteers
S3B10917 Completed Initial safety and tolerability study with intravenous GR68755 in human volunteers.
S3B10919 Completed Initial safety and tolerability study with oral doses of GR68755 in human volunteers.
S3B10924 Completed A study to investigate the duration of effect of oral GR68755 on intradermal 5-HT induced flare response in volunteers
S3B10932 Completed A double-blind, randomized-step study of the effect of alosetron 1 mg, 2 mg, and 4 mg BID versus placebo on QT and QTc following 4 days of administration in healthy females.
S3B10934 Completed An Open-Label, Non-Randomized, Single-Dose Study of the Pharmacokinetics of Alosetron 1mg in Adolescents 12-17 Years of Age With Non-Constipated Irritable Bowel Syndrome
S3B10935 Completed An open-label, non-randomized, two-way cross-over trial to evaluate the effect of multiple-dose alosetron administration (1 mg PO BID for 14 days) on the pharmacokinetics of single-dose fluoxetine (PROZAC) administration in healthy subjects.
S3B10936 Completed An open-label, non-randomized, cross-over trial to evaluate the effect of alosetron (1 mg PO BID for 5 days) on the pharmacokinetics of single-dose amitriptyline (Elavil) administration in healthy subjects.
S3B10937 Completed An open-label, single-dose, randomized, two-period, cross-over trial to evaluate the effect of alosetron (1 mg PO) on the pharmacokinetics of hydrocodone and acetaminophen (VICODIN 5 mg/ 500 mg PO) in healthy subjects.
S3B10938 Completed An open-label, randomized, two-period, cross-over trial to evaluate the effect of alosetron (1 mg PO BID for 2 days) on the pharmacokinetics of single-dose alprazolam (1 mg PO) in healthy subjects.
S3B10939 Completed An open-label, single-dose, randomized, two-period cross-over trial to evaluate the effect of alosetron administration (1 mg PO) on the pharmacokinetics of ibuprofen (600 mg PO) administration in healthy subjects.
S3B10940 Completed A randomised, double-blind, placebo-controlled, cross-over study to investigate the effect of alosetron (GR68755C) on basal jejunal water and electrolyte transport in healthy male subjects.
S3B10942 Completed An open-label study of the pharmacokinetics of a single 1mg oral dose of alosetron in healthy Korean subjects.
S3B10945 Completed A Double-Blind, Randomised, 2-Way Crossover Study to Determine the Effect of Alosetron 1mg BID for 14 days Versus Placebo BID on Visceral Hypersensitivity Following Duodenal Lipid Infusion in Female Diarrhea-Predominant IBS Patients
S3B10946 Completed An open-label parallel-group, pharmacokinetics and tolerability study of a single 1mg oral dose of alosetron in hepatically impaired subjects and in healthy control subjects.
S3B10947 Completed An Open-Label, Non-Randomized, Mass Balance Study to Characterize the Metabolism of Isotopically Labelled Alosetron After a Single 4mg Oral Dose of [13C, 14C]-Alosetron in Healthy Subjects
S3B10948 Completed An open-label, Within-Subject Study to Compare the Pharmacodynamics and Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel 100mg and Ethinyl Estradiol 20mg in Healthy Female Subjects When Administered Alone and Following Co-Administration of Alosetron 1mg BID Orally for 28 Days
S3B20019 Completed A randomized, double-blind, placebo-controlled, crossover evaluation of the effects of GR68755C on plasma levels of haloperidol in patients with a diagnosis of schizophrenia.
S3B20023 Completed A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Phase II Study to Assess the Clinical Efficacy of Alosetron (GR68755) in Male Subjects With Irritable Bowel Syndrome

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.